iMAb delivers readily developable human antibodies for your pipeline
SERVICES
Antibody discovery includes:
- In vitro selection and screening (on cells, proteins or peptides)
- Human/mouse cross-reacting mAb
- IgG reformatting (#species, #isotype, Fc KO or ADCC-enhanced)
- Functional validation (agonist/antagonist/competition/inhibition/ADCC/CDC/...)
TECHNOLOGY
In vitro display technologies offer unique advantages over hybridoma technology, particularly for challenging targets like integral membrane proteins.
iMAb uses proprietary computer-designed synthetic repertoires of human mAbs optimized for diversity, expression, and affinity for in vitro screening.
ABOUT US
iMAb is a biotech company with an integrated approach to develop human antibodies.
The company was spun out from Inserm and uses proprietary know-how and a highly diverse library containing billions of candidate antibodies.
Highlights
- Recognized team of experts in antibody discovery
- Proprietary in vitro optimized human libraries
-
100% delivery track record as of today*
(*) > 30 (academic) programs including: GPCR agonists, enzyme inhibitors, anti-splicing-variants, anti-post-translational modifications, anti-receptor tyrosine kinases, anti-ligand, ... (many of them cross-reactive human/mouse)
Latest news
October 26-29, 2020
Meet iMAb (vitually) at the Bio-Europe digital annual international partnering conference
October, 2020
iMAb and MedXcell partner to develop a novel cell immunotherapy strategy against cancer
September, 2020
iMAb and R-Pharm join forces to develop COVID-19 antibody therapy
July, 2020
iMAb and Eutilex partner to discover immune-oncology antibodies
iMAb - Domain Tx collaboration
June, 2020
iMAb and Domain Tx partner to discover antibody targeting an undisclosed GPCR target for IO therapy
Bio-Europe Spring - Paris, FRANCE
March 23-27, 2020
Meet iMAb at the 14th annual international partnering Bio-Europe conference
January, 2020
iMAb and SATT NORD partner to discover therapeutic antibodies against cancer
11th annual PEGS EUROPE - Lisbon, Portugal
November 18-22, 2019
Meet iMAb at the 11th annual PEGS-Europe, Protein and Antibody Engineering Summit | Booth 438
New Fab library presentated at PEGS 2019 Lisbon by Pierre Martineau,
co-founder of iMAb
BIO-EUROPE 2019 - Hamburg, Germany
November 11-13, 2019
Meet iMAb at the 25th annual BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry
FESTIVAL OF BIOLOGICS 2019 - basel switzerland
October 15-17, 2019
Meet iMAb at the Festival of Biologics, Europe’s most important gathering of senior health and biologic professionals
iMAb - Servier collaboration
September, 2019
iMAb and Servier join forces to discover therapeutic antibodies against autoimmune disease
iMAb - Iama collaboration
July, 2019
iMAb and Iama announce the launch of a discovery program for novel immunotherapy antibodies
June 24-25, 2019
Meet iMAb at the 7th Antibody Industrial Symposium 2019 (AIS2019). This year's topic is “Harnessing the immune system with therapeutic antibodies”
iMAb - ADC Therapeutics collaboration
April 9, 2019
iMAb and ADC Therapeutics team up to discover novel therapeutic human antibodies
FESTIVAL OF BIOLOGICS 2019 - San Diego, USA
March 4-5, 2019
Meet iMAb at the Festival of Biologics, at the Americas Antibody Congress bringing together the pioneers doing the most innovative work within the industry and across the whole value chain.
BIO-EUROPE 2018 - Copenhagen, Danmark
November 5-7, 2018
Meet iMAb at the 24th annual BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry
FESTIVAL OF BIOLOGICS 2018 - basel switzerland
October 29-31, 2018
Meet iMAb at the Festival of Biologics, a technology exhibition for the biologics community gathering 1200 antibody, biosimilar, immunotherapy and high potency API development professionals, as well as leading academics and innovative suppliers.
iMAb, Institut de Recherche en Cancérologie de Montpellier, Campus Val d'Aurelle, 34298 Montpellier cedex 5, France
